Tempus AI (NASDAQ:TEM) CEO Ryan Fukushima Sells 13,550 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 13,550 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $597,148.50. Following the completion of the sale, the chief executive officer owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. This represents a 2.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

NASDAQ TEM opened at $46.49 on Friday. The company has a fifty day simple moving average of $49.02 and a 200 day simple moving average of $59.39. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The company has a market cap of $8.35 billion, a P/E ratio of -27.03 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. During the same quarter last year, the firm posted ($0.24) EPS. Tempus AI’s revenue was up 36.1% compared to the same quarter last year. Sell-side analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Tempus AI by 1,459.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after purchasing an additional 94,783 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in shares of Tempus AI during the third quarter worth $1,695,000. Krane Funds Advisors LLC lifted its position in shares of Tempus AI by 218.2% during the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock worth $2,427,000 after acquiring an additional 19,358 shares in the last quarter. Finally, Aberdeen Group plc lifted its holdings in shares of Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after buying an additional 102,878 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TEM shares. Mizuho started coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 target price on the stock. BTIG Research cut their price target on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a report on Wednesday, February 25th. Guggenheim cut their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Finally, Robert W. Baird started coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.